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Abstract
Background Arterial stiffness is a major risk factor and effective predictor of cardiovascular diseases and a common pathway
of pathological vascular impairments. Homocysteine (Hcy) and uric acid (UA) own the shared metabolic pathways to affect
vascular function. Serum uric acid (UA) has a great impact on arterial stiffness and cardiovascular risk, while the mutual
effect with Hcy remains unknown yet. This study aimed to evaluate the mutual effect of serum Hcy and UA on arterial
stiffness and 10-year cardiovascular risk in the general population. From the perspective of predictive, preventive, and personalized medicine (PPPM/3PM), we assumed that combined assessment of Hcy and UA provides a better tool for targeted
prevention and personalized intervention of cardiovascular diseases via suppressing arterial stiffness.
Methods This study consisted of 17,697 participants from Beijing Health Management Cohort, who underwent health
examination between January 2012 and December 2019. Brachial-ankle pulse wave velocity (baPWV) was used as an index
of arterial stiffness.
Results Individuals with both high Hcy and UA had the highest baPWV, compared with those with low Hcy and low UA (β:
30.76, 95% CI: 18.36–43.16 in males; β: 53.53, 95% CI: 38.46–68.60 in females). In addition, these individuals owned the
highest 10-year cardiovascular risk (OR: 1.49, 95% CI: 1.26–1.76 in males; OR: 7.61, 95% CI: 4.63–12.68 in females). Of
note, males with high homocysteine and low uric acid were significantly associated with increased cardiovascular risk (OR:
1.30, 95% CI: 1.15–1.47), but not the high uric acid and low homocysteine group (OR: 1.02, 95% CI: 0.90–1.16).
Conclusions This study found the significantly mutual effect of Hcy and UA on arterial stiffness and cardiovascular risk using
a large population and suggested the clinical importance of combined evaluation and control of Hcy and UA for promoting
cardiovascular health. The adverse effect of homocysteine on arteriosclerosis should be addressed beyond uric acid, especially
for males. Monitoring of the level of both Hcy and UA provides a window opportunity for PPPM/3PM in the progression
of arterial stiffness and prevention of CVD. Hcy provides a novel predictor beyond UA of cardiovascular health to identify
individuals at high risk of arterial stiffness for the primary prevention and early treatment of CVD. In the progressive stage
of arterial stiffness, active control of Hcy and UA levels from the aspects of dietary behavior and medication treatment is
conducive to alleviating the level of arterial stiffness and reducing the risk of CVD. Further studies are needed to evaluate
the clinical effect of Hcy and UA targeted intervention on arterial stiffness and cardiovascular health.
Keywords Predictive preventive and personalized medicine (PPPM / 3PM) · Arterial stiffness · Brachial-ankle pulse wave
velocity · Homocysteine · Uric acid · Cardiovascular risk · Mutual effect
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Abbreviations
Hcy	Homocysteine
UA	Uric acid
BHMC	Beijing Health Management Cohort
baPWV	Brachial-ankle pulse wave velocity
eNOS	Endothelial nitric oxide synthase
crPWV	Carotid-radial pulse wave velocity
cfPWV	Carotid-femoral artery pulse wave velocity
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SCAF	Subclinical atrial fibrillation
NADPH	Nicotinamide adenine dinucleotide phosphate
XO	Xanthine oxidase
RAAS	Renin-angiotensin system
ROS	Reactive oxygen species
CRP	C-reactive protein
CAVI	Cardio-ankle vascular index
AGEs	Advanced glycation end products

Introduction
Arterial stiffness is a major predictor
of cardiovascular disease
Arterial stiffness, which reflects arterial elasticity and function, increases with age and is affected by health conditions
such as diabetes and hypertension [1–3]. Arterial stiffness
is becoming more prevalent as the population aging and the
increased prevalence of chronic diseases. Previous studies
have discussed the role of arterial stiffness in the pathophysiology of cardiovascular diseases [4]. In addition to causing
vascular damages such as vascular structural changes and
endothelial dysfunction, arterial stiffness is closely associated with increased cardiac load and decreased coronary
perfusion pressure, microvascular ischemia, arterial wave
reflections, renal dysfunction, and other cardiovascular risks
[5, 6]. Population-based studies have shown that arterial
stiffness is an independent risk factor and early predictor of
cardiovascular diseases especially in the high-risk individuals with hypertension, diabetes, or metabolic syndrome [3,
6–8]. Thus, the early prevention and intervention of arterial
stiffness, especially its unfavorable progression, are particularly crucial for suppressing the global health burden
and promoting health quality. The predictive, preventive,
and personalized medicine (PPPM/3PM) aims to develop
predictive diagnostic tool, targeted prevention strategy, and
personalized medical services to the population [9]. Novel
biomarkers for early detection and preventing of arterial
stiffness progression are needed from the standpoint of
PPPM/3PM.

The mutual effect of homocysteine and uric
acid on arterial stiffness status is a bridge
for cardiovascular disease prediction in the context
of PPPM/3PM
As an integrative strategy in health care system, the
PPPM/3PM aims to promote health care-related research
and management based on multidisciplinary expertise
via early prediction of disease predisposition, timely
prevention of disease onset or progression, and personalized treatment of diseases outcomes [10]. Development
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of innovative screening method contributes to promote
population health by health risk assessment, individualized, and cost-effective profiling. It has been highlighted
that homocysteine (Hcy)/uric acid (UA) metabolism and
cardiovascular diseases are several areas considered to be
potentially strongly benefiting from the PPPM/3PM paradigm [11, 12]. Koklesova et al. reported that the metabolic pathway of Hcy is closely related to coronary artery
disease and atherosclerosis, which is of great value for
disease diagnosis and prediction, and helps to optimize
the individualized comprehensive treatment of patients
[11]. Numerous studies have confirmed that high homocysteine (Hcy) and high uric acid (UA) are important risk
factors and predictors of cardiovascular events, including
acute myocardial infarction, atherosclerosis, and stroke
[13]. Both Hcy and UA can mediate vascular endothelial
dysfunction by activating oxidative stress and inhibiting
endothelial nitric oxide synthase (eNOS), and stimulate
the proliferation of vascular smooth muscle cells, resulting in subclinical changes in arterial structure [14–17].
In addition, Hcy and UA are significantly correlated with
arterial stiffness indicators, including carotid-radial pulse
wave velocity (crPWV), brachial-ankle pulse wave velocity (baPWV), or carotid-femoral artery pulse wave velocity (cfPWV) [16, 18, 19]. Recently, Wang et al. reported
the combined effect of Hcy and UA on subclinical atrial
fibrillation (SCAF) [20]. Marković-Boras et al. found
that the combined measurements of serum Hcy and UA
can better assess the risk of acute myocardial infarction
in patients with diabetes [21], indicating that Hcy and
UA have a potential mutual effect on atherosclerosis.
However, the combined effect of Hcy and UA on arterial
stiffness and overall cardiovascular risk in the general
population remains unknown yet. This study assumed
that abnormal metabolism of Hcy and UA could lead to
arterial stiffness by inducing vascular endothelial dysfunction and then increase the risk of cardiovascular
disease. Exploration of mutual effect of Hcy and UA as
biomarkers of arterial stiffness status could inform the
high-risk population to adapt personalized behavior to
moderate the cardiovascular health status from the aspects
of PPPM/3 M.

Aim of this study
From the perspective of PPPM/3 M, effective identification
of risk factors for arterial stiffness is crucial for the lowering the health burden and adverse consequences. This study
aims to investigate the mutual effect of serum Hcy and UA on
arterial stiffness and 10-year cardiovascular risk using a crosssectional design, and evaluate whether effects of homocysteine
and uric acid on arterial stiffness and cardiovascular risk are
distinct between males and females.
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Material and methods
Study population and design
This cross-sectional study enrolled participants from Beijing Health Management Cohort (BHMC) from January
2012 to December 2019. Details of the cohort design have
been described in previous study [22]. All participants
undertook the questionnaire survey, physical examination, and routine laboratory tests. Finally, 17,697 individuals aged 20 years or above, and with required data
were included in this study. This study was in accordance
with the principles of the Declaration of Helsinki and was
approved by the Ethics Committee of Capital Medical University (grant number: 2020SY031). All participants provided their written informed consents before participating
in the current study.

Data measurement and definitions
The demographic characteristics and lifestyle behaviors
factors were acquired by standard questionnaire interview.
Educational level was categorized as illiteracy or primary
school, middle school, high school or above. Taking moderate or intense physical activity “ ≥ 20 min each time
and ≥ 4 times per week” was regarded as regular exercise.
Smoking status was divided into never or former, and current smoker. Individual with an average alcohol consumption of more than 30 g per day was considered as current
drinker.
Physical examination information and laboratory
tests data were acquired through the electronic information system. Body mass index (BMI) was calculated as
weight (kg)/[height (m)*height (m)]. Systolic and diastolic blood pressures were calculated as the mean of two
measurements using the mercury sphygmomanometer on
the right arm after resting for at least 10 min. Laboratory
tests were carried out using fasting venous blood samples including assays for triglyceride, total cholesterol,
high density lipoprotein (HDL) cholesterol, low density
lipoprotein (LDL) cholesterol, fasting plasma glucose,
glycated hemoglobin (HbA1c), serum Hcy, and serum
UA. According to a previous study based on the Chinese
population, high level Hcy was defined as > 14 µmol/L in
males and > 10 µmol/L in females, and high level UA was
defined as > 420 µmol/L in males and > 320 µmol/L in
females [20]. The definition of obesity was BMI ≥ 28 kg/
m 2 for the Chinese population [23]. Hypertension was
defined as systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg or use of any anti-hypertensive medication or self-reported diagnosis history of hypertension

according to the JNC-7 report [24]. Diabetes was defined
as fasting glucose ≥ 7.0 mmol/L, HbA1c ≥ 6.5%, or the use
of any anti-diabetic medication or self-reported diagnosis history of diabetes based on the American Diabetes
Association 2020 report [25]. According to the Guidelines on Prevention and Treatment of Dyslipidaemia for
Chinese Adults, dyslipidemia was defined as triglycerides ≥ 2.3 mmol/L, total cholesterol ≥ 6.2 mmol/L, LDL
cholesterol ≥ 4.1 mmol/L, HDL cholesterol < 1.0 mmol/L,
or any lipid-lowering medication or self-reported diagnosis history of dyslipidemia [26]. Cardiovascular diseases were self-reported in this study, including coronary
heart disease, myocardial infarction, and stroke. Information about use of anti-gout medication and aspirin were
acquired.

BaPWV assessment
The baPWV was automatically measured using Omron
Colin BP-203RPE III device (Omron Health Care, Kyoto,
Japan) as described previously [22]. After more than 5 min
of rest in the supine position, 4 cuffs were wrapped around
the bilateral brachia and ankles and then connected to a plethysmographic sensor and oscillometric pressure sensor.
The time interval between the wave front of the brachial
waveform and the ankle waveform was expressed as the time
interval between the brachium and ankle (∆Tba). The final
baPWV was calculated as baPWV = (La − Lb)/∆Tba. La was
the path length from the suprasternal notch to the ankle, and
Lb was the path length from the suprasternal notch to the
brachium. The maximum value of baPWV measurements on
left and right sides was obtained.

Cardiovascular risk calculation
We used the Framingham Heart Study score to evaluate the
overall 10-year cardiovascular risk [27]. The score includes
age, sex, total cholesterol, HDL cholesterol, systolic blood
pressure, blood pressure lowering medication use, diabetes
status, and smoking status in the primary model for individuals from 30 to 74 years and without cardiovascular disease
history. Individuals with 10-year cardiovascular risk ≥ 20%
were grouped as high risk.
For males, the risk is calculated as 1 − 0.88936exp(ΣβX−23.9802),
where β is the regression coefficient and X is the level for each
risk factor as following equation:
Σ𝛽X = 3.06117 ∗ log(age) + 1.12370 ∗ log(total cholesterol [mg∕dL]) −
0.93263 ∗ log(HDL cholesterol [mg∕dL]) +
0.65451 ∗ smoker [yes or no] + 0.57367 ∗ diabetes [yes or no] +
1.93303 ∗ log(systolic pressure not treated) or
1.99881 ∗ log(systolic pressure treated).
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For females, the risk is calculated as 1 − 0.95012exp(ΣβX−26.1931)
as following equation:
Σ𝛽X = 2.32888 ∗ log(age) + 1.20904 ∗ log(total cholesterol [mg∕dL]) −
0.70833 ∗ log(HDL cholesterol [mg∕dL]) +
0.52873 ∗ smoker [yes or no] + 0.69154 ∗ diabetes [yes or no] +
2.76157 ∗ log(systolic pressure not treated) or
2.82263 ∗ log(systolic pressure treated).

Statistical analysis
The statistical analyses were conducted using R software,
version 4.1.0 (R Foundation). Considering the sex-specific
differences in metabolism of Hcy and UA, all analyses were
stratified by gender. The difference was considered statistically significant at two-side significance level of P < 0.05.
Baseline characteristics are presented as the mean (standard deviation, SD) or median [interquartile range, IQR] or
number (proportions), as appropriate. Differences between
males and females were compared using chi-square test for
categorical variables, and Student’s t test or Mann–Whitney
U test for continuous variables. Differences in baPWV level
among groups divided by Hcy and UA were compared using
Kruskal–Wallis test. The correlations between Hcy and UA
were analyzed using Spearman’s coefficients.
Unadjusted and adjusted linear regression models
were used to estimate the association of Hcy and UA
concentrations with baPWV level. Age, education level,
BMI, physical activity, current smoking, current drinking, hypertension or not, diabetes or not, dyslipidemia or
not, systolic pressure, fasting glucose, triglyceride, and
HDL cholesterol were considered in the adjusted analyses. We calculated the regression coefficient (β) and
corresponding 95% confidence interval (CI) for one-SD
increase of Hcy and UA, respectively. To investigate the
mutual effect between Hcy and UA, the population were
divided into four groups: low Hcy/low UA, high Hcy/
low UA, low Hcy/high UA, and high Hcy/high UA by
sex specific cutoffs. In addition, the associations of Hcy
(UA) concentration with baPWV were presented in people with low and high UA (Hcy) level. Then, we analyzed
the mutual effect of Hcy and UA in subgroups stratified
by age, obesity, hypertension, diabetes, and smoking status. We performed multiple sensitivity analyses. First,
participants with cardiovascular diseases were excluded
from the analysis; second, we excluded the individuals
using any following medications: anti-hypertensive, antidiabetic, lipid-lowering, anti-gout, and aspirin, to explore
the stability of our findings. In addition, we used the
logistics regression models to evaluate the association
of Hcy and UA groups with 10-year cardiovascular risk.
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Results
Population characteristics
The final analysis enrolled a total of 17,697 participants,
including 12,604 men and 5093 women. The mean age
(± SD) was 58.95 (13.99) years in men and 54.81 (14.03)
years in women. The medians [P25–P75] of serum Hcy were
11.8 [9.8 − 14.7] μmol/L for men and 9.0 [7.4–11.0] μmol/L
for women; UA were 372 [323–423] μmol/L for men and
284 [243–330] μmol/L for women; baPWV were 1489
[1345–1713] cm/s for men and 1391 [1252–1595] cm/s for
women. Table 1 shows the detailed characteristics according to sex, and characteristic distribution stratified by UA
and Hcy is shown in Tables S1 and S2. The People with
high Hcy and UA concentrations had the highest baPWV
level, compared with low Hcy/low UA group, high Hcy/
low UA group, and low Hcy/high UA group (Figure S1
A–B). For men, there was a significantly positive correlation
between Hcy and UA levels (Spearman’s coefficient = 0.113;
P < 0.001). Similar result was found for women (Spearman’s
coefficient = 0.225; P < 0.001) as shown in Figure S1 C–D.

Association of Hcy and UA with arterial stiffness
In the adjusted model, one-SD increase in Hcy was associated with a 7.38 (95% CI: 3.98–10.79) cm/s increase
of baPWV in men and an 11.00 (95% CI: 6.33–15.68)
cm/s increase of baPWV in women. Men with high Hcy
(> 14 µmol/L) had a 14.19 (95% CI: 6.60–21.78) cm/s
higher baPWV than those with low Hcy; women with high
Hcy (> 10 µmol/L) had a 21.61 (95% CI: 11.71–31.51)
cm/s higher baPWV. Similarly, 1-SD increase in UA was
associated with a 7.65 (95% CI: 4.11–11.18) cm/s increase
of baPWV in men and a 16.60 (95% CI: 11.56–21.63)
cm/s increase of baPWV in women. Men with high UA
(> 420 µmol/L) had a 14.74 (95% CI: 6.85–22.63) cm/s
higher baPWV than those with low UA; women with high
UA (> 320 µmol/L) had a 38.16 (95% CI: 27.51–48.81) cm/s
higher baPWV. Of note, individuals with both high Hcy and
high UA had a 30.76 (95% CI: 18.36–43.16) cm/s increase
of baPWV in men compared with those with low Hcy and
low UA, which was higher than those just with high Hcy (β:
10.80, 95% CI: 1.85–19.74) or high UA (β: 10.96, 95% CI:
1.41–20.51). Similarly, female individuals with both high
Hcy and high UA had a 53.53 (95% CI: 38.46–68.60) cm/s
increase of baPWV in men compared with those with low
Hcy and low UA, which was higher than those just with high
Hcy (β: 21.63, 95% CI: 9.73–33.53) or high UA (β: 39.77,
95% CI: 26.35–53.19) as shown in Table 2.
Figure 1 demonstrates the associations of one-SD
increase in Hcy among participants grouped by UA status,
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Table 1  Characteristic
distribution of participants

Age (years)
Education (n, %) a
Primary school or below
Middle school
High school or above
Physical activity (n, %) b
Current smoking (n, %)
Current drinking (n, %)
BMI (kg/m2) c
Obesity (n, %) d
SBP (mmHg)
DBP (mmHg)
Triglyceride (mmol/L)
Total cholesterol (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
Fasting glucose (mmol/L)
HbA1c (%)
Health status (n, %)
Hypertension
Diabetes
Dyslipidemia
Cardiovascular diseases
Medication use (n, %)
Antihypertensive
Antidiabetic
Lipid lowering
Anti-gout
Aspirin
Homocysteine (μmol/L)
Uric acid (μmol/L)
BaPWV (cm/s)

Males (n = 12,604)

Females (n = 5093)

P value

58.95 (13.99)

54.81 (14.03)

1030 (8.2)
7545 (59.9)
4029 (32.0)
7229 (57.4)
3062 (24.3)
6301 (50.0)
26.03 (3.07)
2777 (23.2)
128.24 (15.81)
73.01 (10.76)
1.36 [0.98,1.97]
4.52 [3.90,5.17]
2.97 [2.38,3.57]
1.19 [1.03,1.41]
5.37 [4.98,6.01]
5.77 [5.48,6.19]

452 (8.9)
3008 (59.1)
1633 (32.1)
3251 (63.8)
825 (16.2)
1858 (36.5)
24.32 (3.50)
678 (14.1)
119.86 (17.87)
67.99 (10.08)
1.14 [0.82,1.59]
4.76 [4.20,5.39]
3.06 [2.51,3.64]
1.44 [1.20,1.72]
5.06 [4.75,5.47]
5.71 [5.46,6.00]

4192 (33.3)
2166 (17.2)
4761 (37.8)
627 (5.0)

1051 (20.6)
421 (8.3)
1241 (24.4)
144 (2.8)

< 0.001
< 0.001
< 0.001
< 0.001

1734 (13.8)
719 (5.7)
1128 (8.9)
60 (0.5)
439 (3.5)
11.8 [9.8,14.7]
372.0 [323.0,423.0]
1489.0 [1345.0,1713.0]

441 (8.7)
139 (2.7)
372 (7.3)
3 (0.1)
95 (1.9)
9.0 [7.4,11.0]
284.0 [243.0,330.0]
1391.0 [1252.0,1595.0]

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

< 0.001
0.281

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

Data are presented as mean (SD), median [IQR], or number (%), as appropriate
Abbreviations: SD standard deviation, IQR interquartile range, BMI body mass index, SBP systolic blood
pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
lipoprotein cholesterol, HbA1c glycated hemoglobin, baPWV brachial-ankle pulse wave velocity

a

b
c
d

Education level was divided into primary school or below, middle school, and high school or above
Physical activity refers to having moderate or intense exercise ≥ 80 min a week
BMI was calculated as weight in kilograms divided by height in meters squared
Obesity is confirmed by BMI ≥ 28 kg/m2

and the associations of one-SD increase in UA among participants grouped by Hcy status. The effect of Hcy was significant in people with low UA level, and the impact of UA
was dominant in those with low Hcy level for males. For
females, the effect of Hcy was significant in people with
low UA level, while the UA was significantly associated
with baPWV regardless of Hcy level. The regression lines
after adjusting for confounding factors of Hcy and baPWV
stratified by UA status and the regression lines of UA and

baPWV stratified by Hcy status are presented in Fig. 2. The
nomogram of arterial stiffness was drawn based on Hcy and
UA (Figure S2), and the risk assessment algorithm of Hcy
and UA is shown in Table S3.

Sensitivity and subgroup analyses
The consistent results were observed in sensitivity analyses after excluding those with cardiovascular diseases or
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Table 2  Separate and mutual associations of serum Hcy and UA with baPWV in males and females
Adjusted model a

Unadjusted model
β
Males
Hcy (Per-SD: 7.64 μmol/L)
Low Hcy (n = 8896)
High Hcy (n = 3708)
UA (Per-SD: 78.65 μmol/L)
Low UA (n = 9294)
High UA (n = 3310)
Low Hcy and low UA (n = 6731)
High Hcy and low UA (n = 2563)
Low Hcy and High UA (n = 2165)
High Hcy and high UA (n = 1145)
Females
Hcy (Per-SD: 3.98 μmol/L)
Low Hcy (n = 3300)
High Hcy (n = 1793)
UA (Per-SD: 69.22 μmol/L)
Low UA (n = 3588)
High UA (n = 1505)
Low Hcy and low UA (n = 2486)
High Hcy and low UA (n = 1102)
Low Hcy and High UA (n = 814)
High Hcy and high UA (n = 691)

95% CI

P value

β

95% CI

P value

25.372

20.349, 30.394

< 0.001

7.383

3.979, 10.788

< 0.001

94.471
− 4.266

83.530, 105.412
− 9.308, 0.776

< 0.001
0.097

14.193
7.648

6.604, 21.782
4.113, 11.182

< 0.001
< 0.001

4.392

− 7.066, 15.849

0.453

14.740

6.847, 22.633

< 0.001

84.652
− 13.538
105.779

71.664, 97.641
− 27.365, 0.288
87.890, 123.668

< 0.001
0.055
< 0.001

10.795
10.958
30.755

1.846, 19.743
1.405, 20.510
18.355, 43.156

0.018
0.025
< 0.001

63.395

56.112, 70.677

< 0.001

11.003

6.328, 15.679

< 0.001

137.450
84.683

122.242, 152.657
77.569, 91.797

< 0.001
< 0.001

21.612
16.596

11.711, 31.513
11.557, 21.634

< 0.001
< 0.001

165.384

149.624, 181.144

< 0.001

38.164

27.514, 48.814

< 0.001

110.475
139.512
269.763

92.321, 128.629
119.255, 159.769
248.190, 291.335

< 0.001
< 0.001
< 0.001

21.628
39.766
53.527

9.729, 33.527
26.347, 53.186
38.457, 68.598

< 0.001
< 0.001
< 0.001

Abbreviations: Hcy homocysteine, UA uric acid, baPWV brachial-ankle pulse wave velocity
a

Adjusted for age, education, BMI, physical activity, smoking, drinking, health status, systolic pressure, glucose, triglyceride, HDL-C

1 SD (7.64 µmol/L) increase in Hcy (Male)

ß (95%CI)

1 SD (3.98 µmol/L) increase in Hcy (Female)

P value

Crude model

ß (95%CI)

P value

Crude model

UA<420 µmol/L

25.77 (19.60, 31.94)

<0.001

UA<320 µmol/L

48.62 (40.23, 57.01)

<0.001

UA>=420 µmol/L

24.55 (15.83, 33.27)

<0.001

UA>=320 µmol/L

64.45 (51.09, 77.82)

<0.001

Adjusted model

Adjusted model

UA<420 µmol/L

7.85 (3.70, 12.00)

<0.001

UA<320 µmol/L

10.45 (5.18, 15.71)

<0.001

UA>=420 µmol/L

5.16 (−0.86, 11.18)

0.093

UA>=320 µmol/L

8.43 (−1.06, 17.92)

0.082

−20 −10

0

10

20

30

0

1 SD (78.65 µmol/L) increase in UA (Male)

ß (95%CI)

15

30

45

60

75

90

1 SD (69.22 µmol/L) increase in UA (Female)

P value

Crude model

ß (95%CI)

P value

Crude model

Hcy<14 µmol/L

−11.59 (−17.33, −5.85)

<0.001

Hcy<10 µmol/L

72.15 (63.36, 80.94)

<0.001

Hcy>=14 µmol/L

−1.10 (−10.96, 8.75)

0.827

Hcy>=10 µmol/L

78.97 (66.96, 90.98)

<0.001

Adjusted model

Adjusted model

Hcy<14 µmol/L

8.60 (4.43, 12.76)

<0.001

Hcy<10 µmol/L

18.15 (12.03, 24.28)

<0.001

Hcy>=14 µmol/L

3.99 (−2.74, 10.71)

0.245

Hcy>=10 µmol/L

11.51 (2.65, 20.37)

0.011
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Fig. 1  Adjusted associations of one-SD increase in Hcy/UA with
baPWV stratified by UA/Hcy levels. Abbreviations: Hcy homocysteine, UA uric acid, baPWV brachial-ankle pulse wave velocity, SD standard deviation. The SD of UA and Hcy in males was
78.65 µmol/L and 7.64 µmol/L; SD of UA and Hcy in females was
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in the multi-variable linear regression model after adjusted for age,
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systolic pressure, glucose, triglyceride, HDL-C
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Fig. 2  Adjusted linear regression lines of Hcy/UA and baPWV stratified by UA/Hcy levels. Abbreviations: Hcy homocysteine, UA uric
acid, baPWV brachial-ankle pulse wave velocity. High level Hcy
was defined as > 14 µmol/L in male and > 10 µmol/L in female; and
high level UA was defined as > 420 µmol/L in male and > 320 µmol/L
in female. The regression lines were plotted after adjusting for age,
education, BMI, physical activity, smoking, drinking, health sta-
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tus, systolic pressure, glucose, triglyceride, HDL-C using R package ‘effects’. A: linear regression lines of Hcy and baPWV stratified
by UA levels in male; B: linear regression lines of UA and baPWV
stratified by Hcy levels in male; C: linear regression lines of Hcy
and baPWV stratified by UA levels in female; D: linear regression
lines of UA and baPWV stratified by Hcy levels in female

Table 3  Mutual associations of serum Hcy and UA with baPWV in sensitivity analyses
Males

Females

β (95% CI)
Sensitivity 1
(males: 11,977; females: 4949)
Low Hcy and low UA (males: 6423; females: 2447)
High Hcy and low UA (males: 2421; females: 1077)
Low Hcy and High UA (males: 2077; females: 784)
High Hcy and high UA (males: 1056; females: 641)
Sensitivity 2
(males: 10,313; females: 4472)
Low Hcy and low UA (males: 5518; females: 2291)
High Hcy and low UA (males: 2085; females: 964)
Low Hcy and High UA (males: 1793; females: 692)
High Hcy and high UA (males: 917; females: 525)

P value

β (95% CI)

P value

9.559 (0.486, 18.631)
9.675 (0.041, 19.310)
31.104 (18.413, 43.795)

0.039
0.049
< 0.001

22.453 (10.541, 34.364)
39.588 (26.105, 53.071)
53.142 (37.869, 68.414)

< 0.001
< 0.001
< 0.001

12.451 (2.654, 22.248)
9.965 (− 0.407, 20.338)
34.165 (20.520, 47.809)

0.013
0.060
< 0.001

22.839 (10.692, 34.987)
37.633 (23.743, 51.523)
55.306 (39.268, 71.344)

< 0.001
< 0.001
< 0.001

β is adjusted for age, education, BMI, physical activity, smoking, drinking, health status, systolic pressure, glucose, triglyceride, HDL-C
Sensitivity 1: Excluding participants with cardiovascular diseases; Sensitivity 2: Excluding participants using medications, including anti-hypertensive, anti-diabetic, lipid-lowering, anti-gout, and aspirin
Abbreviations: Hcy homocysteine, UA uric acid, baPWV brachial-ankle pulse wave velocity

excluding those using any anti-hypertensive, anti-diabetic,
lipid-lowering, anti-gout, or aspirin medications, which
could impact the value of Hcy, UA, or baPWV. The detailed

results are shown in Table 3. The mutual effect of Hcy and
UA in subgroups stratified by age, obesity, hypertension,
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Male

Female

ß 95% CI

Age >60 years (N=5044)
Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

59.508(41.572, 77.444)
14.215(−8.761, 37.192)
96.393(71.538, 121.247)

Age ≤60 years (N=7560)

ß 95% CI

Age >60 years (N=1617)
Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

36.921(6.255, 67.588)
39.31(4.836, 73.784)
99.139(66.901, 131.378)

Age ≤60 years (N=3476)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

−1.358(−11.865, 9.149)
7.169(−2.851, 17.188)
20.541(5.993, 35.089)

BMI ≥28.0 kg/m2 (N=2777)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

31.531(18.353, 44.709)
48.381(33.478, 63.284)
79.076(59.934, 98.218)

BMI ≥28.0 kg/m2 (N=678)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

2.322(−16.802, 21.447)
−10.117(−27.791, 7.556)
10.819(−12.219, 33.856)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

13.17(3.045, 23.296)
18.384(7.010, 29.759)
38.072(23.363, 52.78)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

13.962(−3.352, 31.276)
9.871(−9.459, 29.200)
26.026(3.248, 48.803)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

8.972(−1.228, 19.172)
12.232(1.593, 22.871)
35.338(20.74, 49.935)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

25.201(1.439, 48.962)
18.397(−10.549, 47.343)
20.482(−14.798, 55.762)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

7.750(−1.859, 17.359)
8.812(−1.210, 18.834)
32.489(19.363, 45.614)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

−4.290(−21.918, 13.337)
20.828(1.272, 40.383)
39.908(15.491, 64.326)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

15.899(5.514, 26.285)
8.127(−2.818, 19.073)
26.791(12.391, 41.191)

BMI <28.0 kg/m2 (N=9191)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

52.446(11.595, 93.296)
40.741(3.461, 78.021)
46.456(8.209, 84.702)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

17.419(5.12, 29.718)
39.248(24.804, 53.692)
59.896(43.307, 76.485)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

−17.822(−54.715, 19.07)
22.5(−15.135, 60.135)
22.837(−14.303, 59.978)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

29.753(17.904, 41.601)
41.286(27.496, 55.075)
62.386(45.958, 78.814)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

92.717(27.04, 158.393)
129.059(67.033, 191.085)
152.588(88.374, 216.802)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

17.571(5.764, 29.378)
32.752(19.184, 46.319)
44.584(29.157, 60.011)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

7.592(−23.794, 38.978)
34.985(1.167, 68.803)
62.605(21.442, 103.769)

Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

24.257(11.402, 37.112)
40.593(25.951, 55.236)
51.854(35.642, 68.066)

BMI <28.0 kg/m2 (N=4147)

With hypertension (N=4192)

With hypertension (N=1051)

Without hypertension (N=8412)

Without hypertension (N=4042)

With diabetes (N=2166)

With diabetes (N=421)

Without diabetes (N=10438)

Without diabetes (N=4672)

Smoker (N=3062)

Smoker (N=825)

Non-smoker (N=9542)

Non-smoker (N=4268)
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Fig. 3  Adjusted mutual associations of serum Hcy and UA with
baPWV in subgroups according to age, BMI, hypertension, diabetes, and smoking. Abbreviations: Hcy homocysteine, UA uric acid,
baPWV brachial-ankle pulse wave velocity. High level Hcy was
defined as > 14 µmol/L in males and > 10 µmol/L in females; and high

level UA was defined as > 420 µmol/L in males and > 320 µmol/L in
females. Age was divided in to ≤ 60 and > 60 years; BMI was divided
in to ≥ 28.0 and < 28.0 kg/m2 according to the standard for Chinese
population

diabetes, and smoking status is summarized in Fig. 3. For
males, the mutual effects of Hcy and UA were significant in
all subgroups, apart from those with obesity or diabetes. For
females, the mutual effects were significant in all subgroups,
apart from those with hypertension.

note, males with high Hcy and low UA were significantly
associated with increased cardiovascular risk (OR: 1.30,
95% CI: 1.15–1.47), but not the high UA and low Hcy group
(OR: 1.02, 95% CI: 0.90–1.16). The nomogram of 10-year
CVD risk was drawn based on Hcy and UA (Figure S3), and
the risk assessment algorithm of Hcy and UA is shown in
Table S3.

Mutual effect of Hcy and UA on 10‑year
cardiovascular risk
In addition, we calculated the 10-year cardiovascular risk for
14,251 individuals between 30 and 74 years old without cardiovascular diseases history. People with both high Hcy and
UA had the highest cardiovascular risk, and the OR was 1.49
(95% CI: 1.26–1.76) in males and 7.61 (95% CI: 4.63–12.68)
in females (Table 4). Females with high Hcy/low UA or high
UA/low Hcy were both associated with increased 10-year
cardiovascular risk, and the OR values were 2.85 (95% CI:
1.68–4.84) and 3.10 (95% CI: 1.78–5.38), respectively. Of
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Discussion
Paradigm shift from reactive medicine
to the advanced PPPM/3 M
This study aimed to investigate the mutual effect of serum
Hcy and UA on arterial stiffness in the general population.
The results showed that high Hcy or high UA was significantly correlated with increased baPWV level. Individuals
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Table 4  Mutual association of
serum homocysteine and uric
acid with 10-year cardiovascular
risk a

Males

Females

OR (95% CI)
Low Hcy and low UA
High Hcy and low UA
Low Hcy and High UA
High Hcy and high UA

Reference
1.303 (1.150–1.473)
1.024 (0.902–1.160)
1.492 (1.261–1.761)

P value
< 0.001
0.712
< 0.001

OR (95% CI)
Reference
2.849 (1.683–4.844)
3.095 (1.775–5.377)
7.607 (4.629–12.681)

P value
< 0.001
< 0.001
< 0.001

The 10-year risk for men can be calculated as 1 − 0.88936exp(ΣβX−23.9802), where β is the regression coefficient and X is the level for each risk factor as following equation: ΣβX = 3.06117*log(age) + 1.1237
0*log(total cholesterol [mg/dL]) − 0.93263*log(HDL cholesterol [mg/dL]) + 0.65451*smoker [yes or
no] + 0.57367*diabetes [yes or no] + 1.93303*log(SBP not treated) or 1.99881*log(SBP treated)

The 10-year risk for women can be calculated as 1 − 0.95012exp(ΣβX−26.1931): ΣβX = 2.32888*log(age) + 1.
20904*log(total cholesterol [mg/dL]) − 0.70833*log(HDL cholesterol [mg/dL]) + 0.52873*smoker [yes or
no] + 0.69154*diabetes [yes or no] + 2.76157*log(SBP not treated) or 2.82263*log(SBP treated)
Individuals with 10-year cardiovascular risk ≥ 20% are grouped as high risk
Abbreviations: Hcy homocysteine, UA uric acid, SBP systolic blood pressure
a

The general cardiovascular risk is calculated using the Framingham Heart Study 10-year risk score. The
score includes age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering
medication use, diabetes status, and smoking status in the primary model

with both high Hcy and high UA had the highest level of
arterial stiffness and 10-year cardiovascular risk than those
with high Hcy or high UA alone. In addition, Hcy and UA
have shown potential as biomarkers in the assessment of
arterial stiffness and CVD risk. Of note, males of high Hcy
and low UA had increased cardiovascular risk, but not high
UA and low Hcy, which partly implies males suffer more
from Hcy than females, and females are more sensitive to
UA than males.
From the perspective of PPPM/3 M, identification of
cost-effective and reliable biomarkers is important for the
prevention of diseases. The monitoring of these biomarkers could provide predictive information on the onset or
prognosis of adverse events. People with high risk should
adapt pharmaceutical or non-pharmaceutical interventions
to alleviate the progression, which effectively contribute to
the paradigm shift from reactive medicine to the advanced
approach by utilizing PPPM/3 M concepts [28, 29]. The
reactive PPPM/3 M paradigm has been applied in many
fields and greatly contributes to the health quality promotion. Golubnitschaja et al. emphasized the basic principle
of personalized medicine “one size does not fit all” in BMI
management. Individually optimal weight should be clearly
discriminated and underlined from the standardized “normal” body weight [30]. Polivka et al. summarized the traditional (sedentary lifestyle, smoking, abnormal alcohol consumption, drug abuse, overweight, hypertension, abnormal
sleep patterns) and less explored risk factors (primary vascular dysregulation and associated symptoms characteristic for Flammer syndrome) for young stroke and supported
innovative screening programs by application of specialized

questionnaires and biomarker panels as well as educational
programs adapted to the target population [31]. The risk
assessment and patient stratification for breast cancer are
emphasized to providing functional links and proposing new
approaches from the PPPM/3 M perspective [32]. Innovative
screening program is supposed to identify persons in suboptimal health conditions before the clinical onset of metastasizing prostate cancer, and thus to promote the shift of medical paradigm from reactive to advanced PPPM/3M [33]. In
previous studies, arterial stiffness is an important risk factor
and independent predictor of CVD. BaPWV, as a measure of
arterial stiffness, has a great value in guiding clinical treatment and predicting prognosis [34]. In this study, we evaluated the mutual effect of Hcy and UA on arterial stiffness as
measured by baPWV to provide a scientific basis for early
identification of high-risk population for arterial stiffness,
so as to achieve early prediction and primary prevention of
arterial stiffness, and proposed the potential mechanism of
occurrence and progression of arterial stiffness based on Hcy
and UA metabolism.

Shift from single to mutual effect of Hcy and UA
on arterial stiffness
Arterial stiffness is one of the pathological mechanisms of
cardiovascular disease and an independent risk factor of
all-cause mortality [35]. A prospective nested case–control
study showed that high Hcy is significantly associated with
an increased risk of stroke [36]. Rotterdam study showed that
high UA is an important risk factor of stroke and myocardial
infarction [37]. Numerous studies have shown that both Hcy
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and UA levels are significantly positively correlated with the
risk of cardiovascular events [38, 39]. Of note, Hcy and UA
are thought to mediate adverse cardiovascular events through
arterial stiffness [16, 40]. Previous population-based studies
have shown that high Hcy or high UA is an independent risk
factor of arterial stiffness [19, 41]. However, studies on the
effect of Hcy and UA on arterial stiffness are mostly limited
to people with high risk of cardiovascular diseases, such as
hypertension, diabetes, and metabolic syndrome. Evidence
on the association between serum Hcy, UA, and their combined effects and arterial stiffness in the general population
are still lacking. Recently, Wang et al. reported the combined
effect of Hcy and UA on subclinical atrial fibrillation [20],
and our study supplemented the evidence of the combined
effect of Hcy and UA on arterial stiffness.
This study showed that high Hcy and high UA are positively correlated with arterial stiffness in general population
after adjusting for confounding factors. Consistent with our
findings, Chen et al. found that serum Hcy level is positively
correlated with cfPWV level [15]. Wang et al. showed that
the baseline level of Hcy is significantly correlated with the
increase of cfPWV and crPWV at follow-up [19]. Similarly,
several studies have investigated the association between UA
and arterial stiffness. Framingham Heart Study showed that
serum UA levels are significantly associated with cfPWV
and crPWV in the general population [42]. Several prospective cohort studies showed that higher UA level at baseline is
significantly associated with arterial stiffness level at followup [43]. In this study, we found that individuals with both
high Hcy and high UA have the higher level of arterial stiffness than those with high Hcy or high UA alone, suggesting
the combined effect of Hcy and UA on arterial stiffness.
Wang et al. showed that people with both high Hcy and high
UA have the highest risk of SCAF. In addition, the combination of Hcy and UA significantly improves the predictive
capacity of SCAF [20]. Furthermore, population-based studies have reported that Hcy level is positively correlated with
UA [44], suggesting that vascular damages causing atherosclerotic diseases may be attributed to the combined effect
of Hcy and UA.
Vascular endothelium maintains vascular homeostasis by
regulating vascular tension, inflammation, and cell growth
[45]. Endothelial dysfunction triggers inflammatory activation of endothelial cells, resulting in up-regulation of adhesion molecules and chemokines, and release of cytokines
and growth factors to act on adjacent tissues, inducing
smooth muscle cell proliferation, vascular wall remodeling
and fibrosis, and progression to vascular stiffness [1]. Hcy
is a thiol-containing amino acid with cytotoxicity and is an
important intermediate product produced in the metabolism
of methionine and cysteine [40]. It has been reported that
elevated Hcy level can lead to oxidative damage and vascular endothelial dysfunction by reducing methylation [46],
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reducing endogenous H2S production [47], up-regulating
the expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [48], and uncoupling of eNOS [49].
In addition, Hcy can mediate vascular injury through the
protein N-homocysteinylation [50]. UA is the end product
of human exogenous and endogenous purine metabolism.
At the end of purine metabolism, xanthine is oxidized by
xanthine oxidase (XO) to form the final product UA [51].
UA is an effective antioxidant component in plasma at
physiological concentration [52], but high UA can reduce
NO production, induce oxidative stress and inflammatory
response by inhibiting eNOS activity, activating the reninangiotensin system (RAAS) and other pathways [53–55].
Urate crystals produced when serum UA levels exceed the
solubility limit induce inflammation and collagen formation,
causing vascular damage [56]. On the other hand, UA can
cause vascular injury by mediating endothelial dysfunction,
and UA is a marker of the up-regulation of XO activity.
XO is the main source of reactive oxygen species (ROS)
in human body, and the increase of UA level may indicate
the oxidative damage caused by XO to vascular endothelium by increasing ROS [57]. Furthermore, Hcy and UA
have some shared pathways to affect vascular wall structure and function, such as reducing NO bioavailability by
inducing the production of endogenous nitric oxide synthase
inhibitor asymmetric dimethylarginine [58, 59], promoting
inflammation by activating NF-κB signaling and inducing
up-regulation of C-reactive protein (CRP) expression [60,
61], and increasing atherosclerotic disease risk by oxidizing
low-density lipoprotein [62, 63]. These results may explain
the mutual effect of Hcy and UA on endothelial dysfunction
and arterial stiffness. In addition, methionine was converted
to adenosine l-homocysteine and further decomposed to
homocysteine and adenosine. Part of adenosine was further
metabolized to hypoxanthine and entered the UA metabolic
pathway, suggesting a potential association between Hcy and
UA [16, 20]. Further mechanic studies are needed to clarify
the combined role of Hcy and UA in arterial stiffness.

Stratified analysis of the mutual effects of Hcy
and UA on arterial stiffness based on multiple trait
subgroups
Stratified analysis showed that Hcy is positively associated
with arterial stiffness in people with low UA levels, and UA
is positively correlated with arterial stiffness regardless of
Hcy level in females, but positively correlated with arterial
stiffness only at low Hcy level in males (Hcy < 14 µmol/L).
Similarly, Sugiura et al. found that UA is significantly correlated with cardio-ankle vascular index (CAVI) in both
genders, and UA has a greater impact in females than
males [64]. Fang et al. found that high UA level is positively correlated with the increase of baPWV in females, but
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not in males [65]. In addition, some studies have reported
a stronger association between UA and arterial stiffness
in females [16]. The gender difference in the association
between UA and arterial stiffness may be caused by the different distribution of Hcy, which also suggests the interactive
effect between UA and Hcy. The effect of UA on the risk of
arterial stiffness is independent of Hcy in females, whereas
the risk of arterial stiffness caused by UA is not significant
in males with high Hcy. In addition, Chou et al. found that
UA is more strongly associated with insulin resistance and
glucose levels in females than males [66]. Hyperglycemia
stimulates vascular wall proteins to form advanced glycation
end products (AGEs) through non-enzymatic protein glycation, forming irreversible cross-links between proteins [67].
Insulin resistance mediates vascular endothelial dysfunction
through decreased NO bioavailability and oxidative stress
[68], which partially explains the strong risk of UA-related
arterial stiffness.
Golubnitschaja et al. demonstrated that overweight or
underweight can increase metabolic load and reduce adaptive capacity through up-regulation of inflammatory signals
and increased ROS levels [30]. According to our result stratified by BMI, both high Hcy and UA were significantly positively associated with arterial stiffness in underweight men
and overweight and underweight women, suggesting their
negative effects on metabolism in the context of abnormal
weight (Fig. 3). Flammer Syndrome is a clinical symptom
characterized by small body size and low BMI, which is
caused by abnormal blood supply due to primary vascular
dysregulation [69]. Studies have shown that Flammer Syndrome is closely associated with the progression of various
diseases such as glaucomatous optic neuropathy and breast
cancer [70]. Whether Flammer Syndrome is the cause of
reduced BMI in some people at increased risk of arterial
stiffness and whether it is associated with arterial stiffness
and CVD need further exploration.

Association and predictive efficacy of Hcy and UA
with 10‑year CVD risk
In our subsequent analysis of the association of UA and Hcy
with 10-year CVD risk, people with both high UA and Hcy
showed the highest risk, supporting our hypothesis that UA
and Hcy can mediate CVD by causing arterial stiffness. The
study by Zheng et al. suggests that ischemic stroke can be
predicted based on routine hematological and biochemical
features, and early identification of disease risk may facilitate the formulation of primary care strategies and improve
the prognosis of the disease [71]. In this study, the nomogram of CVD risk assessment based on Hcy and UA indicators showed that high Hcy and UA levels predicted the
increase of 10-year CVD risk, and the CVD risk was highest
when both of them were at high levels. This quantitative risk

prediction can identify people at high CVD risk early, and
our study suggests that high Hcy and high UA lead to the
occurrence of CVD by inducing arterial stiffness. Therefore,
timely intervention in the high CVD risk population identified by the model through diet, physical activity, or medication treatment to control the arterial stiffness process early
can effectively achieve the primary prevention of CVD. Of
note, there was no significantly increased CVD risk in males
with high UA and low Hcy, indicating that the impact of Hcy
on CVD risk is more obvious than UA in males. Barbieri
et al.’s study also showed that high UA level was only associated with severe coronary artery disease in females [72],
suggesting the sex difference in UA induced CVD risk. In
addition, the findings underline the adverse effect of Hcy on
arteriosclerosis and cardiovascular risk and emphasize the
clinical importance of combined evaluation and control of
Hcy and UA. Hcy and UA provide new targets and insights
for the primary prevention and intervention of CVD. People
with both high UA and Hcy should pay additional attention
to the arterial stiffness susceptibility and CVD risk apart
from the instinct metabolic disorders. The dietary behavior
and physical activity should be underlined for these people.
In addition, this study suggested that Hcy/UA metabolic disorders could cause CVD progression via arterial stiffness,
and the biological pathway should be further validated in
mechanical researches.

Comprehensive prevention and control of arterial
stiffness
Hcy and UA levels are regulated by both heredity and environmental factors [40, 51]. Improving lifestyle, persisting in
physical exercise, ensuring the intake of folic acid and vitamin B12, and reducing the intake of food with high purine
content can effectively control the levels of internal Hcy and
UA, and thus reduce the arterial stiffness level and cardiovascular risk [73, 74]. Endothelial-dependent vasodilation
is effectively improved after treatment with XO inhibitors
allopurinol or oxypurinol in patients with coronary artery
disease or congestive heart failure [75, 76]. This study indicates the mutual effect of Hcy and UA on arterial stiffness,
further suggesting the important role of combined evaluation
and control of Hcy and UA in preventing arterial stiffness
and cardiovascular events.

Strength and limitations
This study found the mutual effect of Hcy and UA on arterial stiffness and cardiovascular risk based on a large sample
population, and realized early identification of CVD high-risk
groups based on Hcy and UA indicators, which contributes to
the early comprehensive prevention and control of CVD. The
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results should be interpreted in the context of some limitations.
First, this study is based on a cross-sectional design, and the
causal associations of serum Hcy and UA with arterial stiffness
cannot be claimed. And the combined effect of Hcy and UA on
the dynamic changes of arterial stiffness needs further investigation using longitudinal cohort data. Moreover, the effect of
combined control of Hcy and UA on arteriosclerosis and cardiovascular health warrants explanation in clinical trials. Second,
the baPWV index measures stiffness of the elastic aorta and
the muscular arteries, while the aortic stiffness and muscular
stiffness tend to change in the opposite direction with aging.
However, baPWV level still enhances the efficacy of predicting cardiovascular events over the Framingham risk score and
reflects the cardiovascular risk especially in the Asian population. The association of Hcy and UA with arterial stiffness and
screening methods for high-risk CVD patients need further
validation in other populations and using other arterial stiffness
index, such as cfPWV and the direct measurement of arterial stiffness like elastography. In addition, based on previous
studies, we know that the primary prevention and treatment
of arterial stiffness and CVD need to be integrated with diet,
physical activity, and medication treatment, but how to target
the abnormal metabolism of Hcy and UA to comprehensively
prevent and treat arterial stiffness needs to be further explored.

Conclusion and expert recommendations
This study indicates the significant mutual effect of elevated
Hcy and UA on arterial stiffness and 10-year cardiovascular
risk in the general population. The adverse effect of Hcy
on cardiovascular health should be underlined beyond UA,
especially for males. Our study suggested the clinical importance of combined evaluation and control of Hcy and UA
for preventing arterial stiffness and cardiovascular diseases,
and quantified and visualized the risk of arterial stiffness
and 10-year CVD by nomogram, which provides a basis for
early identification of the progression of arterial stiffness and
prediction of CVD risk in general population (Predictive).
Hcy and UA could be novel indicators of arterial stiffness, providing new insights for the early predictive medical
approach of CVD risk in the setting of PPPM/3PM health care
system. The monitoring of Hcy and UA levels could provide
a window opportunity for the primary targeted prevention for
the progression of arterial stiffness and adverse CVD events.
The health care providers should be aware of the CVD risk
for people with Hcy/UA metabolic disorders (Preventive).
Besides, pharmaceutic and non-pharmaceutic interventions
are needed for alleviating the arterial stiffness progression
from the perspective of Hcy and UA using PPPM/3PM strategy, such as balanced diet and physical activity. According to
the risk assessment results based on clinical indicators including Hcy and UA, primary prevention or early treatment of
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arterial stiffness in high-risk groups is of great significance
to control the progression of arterial stiffness and reduce the
risk of CVD (Personalized medicine).
Overall, there is a mutual effect of Hcy and UA on arterial
stiffness and cardiovascular risk, and further studies should
investigate the practical benefits of monitoring Hcy and UA
levels for cardiovascular health promoting, including the
predictive diagnostics, effective prevention, and personalized intervention. This supports the PPPM/3PM strategy and
paradigm shift from reactive to advanced in cardiovascular
health field. People with both high Hcy and UA should be
aware of the cardiovascular health issues at an early stage and
get personalized advice on social activity and support, family
care, dietary behavior, physical activity, and even the pharmaceutical intervention. Hcy/UA metabolic disorders and cardiovascular adverse events could form a vicious circle, which
should be underlined in the advanced PPPM/3PM paradigm.
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